Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Asthma
•
Eosinophilic Disorders
Is it safe to administer benralizumab with rituximab?
Related Questions
Do you utilize cytokine panels to guide treatment of patients with EGPA?
Is there a specific group of children that you start on AIT for prevention of asthma?
Do you withhold performing skin testing for aeroallergens, foods or venoms based on poor lung function?
Would you stop Dupixent in an asthma patient who has good asthma control and notes improvement in loss of smell, but shows notable eosinophil elevation after 4-5 doses of the medication?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
Is there any genetic testing available for the CDHR3 receptor?
Do you generally favor nebulizers, HFAs or other devices in children aged 5 and younger with asthma?
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
Should a patient on medium-dose ICS/LABA with normal PFTs, but who shows a greater than 10% decrease in FEV1 if their PFTs are done after 24 hours off their inhaler, be started on a biologic?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
